Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Sets New 1-Year High – Time to Buy?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)’s share price reached a new 52-week high during trading on Wednesday. The company traded as high as $83.78 and last traded at $83.17, with a volume of 1,235,582 shares changing hands. The stock had previously closed at $79.48.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wedbush upped their target price on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. upped their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 29th. Finally, The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Eight investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $93.14.

Kiniksa Pharmaceuticals International Stock Performance

The stock’s 50 day simple moving average is $78.13 and its two-hundred day simple moving average is $64.98. The firm has a market capitalization of $6.30 billion, a PE ratio of 83.29 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. The company had revenue of $243.60 million for the quarter, compared to the consensus estimate of $226.49 million. Equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Michael Megna sold 4,600 shares of the company’s stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at $2,333,678.60. This represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 51.98% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Rubric Capital Management LP boosted its stake in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the period. Dimensional Fund Advisors LP increased its position in shares of Kiniksa Pharmaceuticals International by 18.8% during the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares during the last quarter. Spruce Street Capital LP raised its stake in shares of Kiniksa Pharmaceuticals International by 75.0% in the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the period. Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the period. Finally, Rice Hall James & Associates LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 2.0% in the 1st quarter. Rice Hall James & Associates LLC now owns 608,416 shares of the company’s stock valued at $29,295,000 after acquiring an additional 11,985 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.